10.1016/j.jff.2016.04.029 J Funct Foods
The GLOW 70 matrix operates on a "Structure-Supply-Mobility" model, where each peptide compensates for the rate-limiting steps of the others
Key tips for underwriting applicants with GLP1 use Immediately look for: Evidence of the underlying diagnosis (as seen in medical claims, EHR, APS) Whether the GLP-1 is FDA-approved or off-label for that condition Signs of medication adherence (12 months, regular fills) Get cautious when: A GLP1 appears without any supporting clinical context Fills are intermittent or recently initiated Theres no alignment between the medication and expected companion therapies (e.g., no CPAP with sleep apnea) Be confident when: The diagnosis is clear The drug is first line and clinically appropriate Use has been stable long enough to confer benefit Kyle Schimek, PharmD Kyle Schimek is a board-certified pharmacist and Clinical Services Manager at Milliman IntelliScript
Three doses per week can theoretically maintain adequate levels
The most one can say is mechanistic: raising GH and IGF-1 could, in principle, influence body composition and metabolism, and the animal models show effects on growth and body composition in a deficiency setting
Klopp also discusses his current work with Red Bull, mentoring young coaches and sporting directors, and addresses the possibility of returning to management in the future
